Charles Schwab Investment Management Inc Biogen Inc. Transaction History

Charles Schwab Investment Management Inc

$519 Billion
Q2 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Biogen Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 900,710 shares of BIIB stock, worth $174 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

900,710

Previous 858,805 4.88%

Holding current value

$174 Million

Previous $185 Million 12.75%

% of portfolio

0.04%

Previous 0.04%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$190.52 - $236.72 $7.98 Million - $9.92 Million	41,905 Added 4.88%	900,710 $209 Million
Q1 2024 May 08, 2024	BUY	$212.02 - $267.71 $2.08 Million - $2.62 Million	9,805 Added 1.15%	858,805 $185 Million
Q4 2023 Feb 06, 2024	BUY	$222.59 - $267.94 $69,002 - $83,061	310 Added 0.04%	849,000 $220 Million
Q3 2023 Nov 08, 2023	SELL	$253.3 - $285.89 $382,736 - $431,979	-1,511 Reduced 0.18%	848,690 $218 Million
Q2 2023 Aug 09, 2023	BUY	$275.25 - $318.06 $1.6 Million - $1.85 Million	5,819 Added 0.69%	850,201 $242 Million
Q1 2023 May 11, 2023	BUY	$256.56 - $292.34 $2.08 Million - $2.36 Million	8,088 Added 0.97%	844,382 $235 Million
Q4 2022 Feb 13, 2023	BUY	$252.44 - $306.72 $3.97 Million - $4.82 Million	15,726 Added 1.92%	836,294 $232 Million
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $5.97 Million - $8.24 Million	30,684 Added 3.88%	820,568 $219 Million
Q2 2022 Aug 15, 2022	BUY	$187.54 - $223.02 $4.71 Million - $5.6 Million	25,124 Added 3.29%	789,884 $161 Million
Q1 2022 May 13, 2022	BUY	$193.77 - $244.14 $4.46 Million - $5.62 Million	23,023 Added 3.1%	764,760 $161 Million
Q4 2021 Feb 11, 2022	BUY	$223.92 - $287.77 $2.36 Million - $3.03 Million	10,539 Added 1.44%	741,737 $178 Million
Q3 2021 Nov 16, 2021	BUY	$282.99 - $369.05 $2.09 Million - $2.72 Million	7,369 Added 1.02%	731,198 $207 Million
Q2 2021 Aug 16, 2021	BUY	$259.0 - $414.71 $5.07 Million - $8.11 Million	19,565 Added 2.78%	723,829 $251 Million
Q1 2021 May 17, 2021	SELL	$242.95 - $284.63 $1.49 Million - $1.75 Million	-6,138 Reduced 0.86%	704,264 $197 Million
Q4 2020 Feb 16, 2021	SELL	$236.26 - $355.63 $5.83 Million - $8.78 Million	-24,678 Reduced 3.36%	710,402 $174 Million
Q3 2020 Nov 13, 2020	SELL	$264.77 - $305.71 $24 Million - $27.7 Million	-90,630 Reduced 10.98%	735,080 $209 Million
Q2 2020 Aug 14, 2020	SELL	$258.66 - $342.55 $29 Million - $38.4 Million	-112,088 Reduced 11.95%	825,710 $221 Million
Q1 2020 May 15, 2020	BUY	$268.85 - $341.04 $932,102 - $1.18 Million	3,467 Added 0.37%	937,798 $297 Million
Q4 2019 Feb 07, 2020	SELL	$220.06 - $304.07 $7.38 Million - $10.2 Million	-33,539 Reduced 3.47%	934,331 $277 Million
Q3 2019 Nov 08, 2019	BUY	$217.44 - $243.88 $7.97 Million - $8.93 Million	36,633 Added 3.93%	967,870 $225 Million
Q2 2019 Aug 09, 2019	BUY	$219.29 - $241.72 $3.27 Million - $3.61 Million	14,919 Added 1.63%	931,237 $218 Million
Q1 2019 May 14, 2019	BUY	$216.71 - $338.96 $1.5 Million - $2.35 Million	6,944 Added 0.76%	916,318 $217 Million
Q4 2018 Feb 14, 2019	BUY	$278.5 - $352.75 $5.94 Million - $7.52 Million	21,321 Added 2.4%	909,374 $274 Million
Q3 2018 Nov 13, 2018	SELL	$293.51 - $383.83 $9.55 Million - $12.5 Million	-32,534 Reduced 3.53%	888,053 $314 Million
Q2 2018 Aug 08, 2018	BUY	$257.52 - $306.91 $7.32 Million - $8.73 Million	28,440 Added 3.19%	920,587 $267 Million
Q1 2018 May 07, 2018	BUY	$260.13 - $367.91 $15.5 Million - $21.9 Million	59,509 Added 7.15%	892,147 $244 Million
Q4 2017 Jan 17, 2018	BUY	$307.64 - $344.58 $17.3 Million - $19.4 Million	56,333 Added 7.26%	832,638 $265 Million
Q3 2017 Nov 13, 2017	BUY	$281.15 - $329.69 $218 Million - $256 Million	776,305	776,305 $243 Million

Others Institutions Holding BIIB

# of Institutions

1,050

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $27.9B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Biogen Inc. Transaction History